| Title: |
Antisense Therapeutics for Tumor Treatment: The TGF-beta2 Inhibitor AP 12009 in Clinical Development Against Malignant Tumors. |
| Authors: |
Riess, Hanno1; Goerke, Andrea1; Oettle, Helmut1; Schlingensiepen, Karl-Hermann2; Fischer-Blass, Birgit2; Schmaus, Susanne2; Ludwig, Sylvia2 |
| Source: |
Pancreatic Cancer (978-3-540-71266-4). 2008, p137-150. 14p. |
| Abstract: |
Overexpression of the cytokine transforming growth factor-beta 2 (TGF-beta2) is a hallmark of various malignant tumors including pancreatic carcinoma, malignant glioma, metastasizing melanoma, and metastatic colorectal carcinoma. This is due to the pivotal role of TGF-beta2 as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. The antisense technology is an innovative technique offering a targeted approach for the treatment of different highly aggressive tumors and other diseases. Antisense oligonucleotides are being developed to inhibit the production of disease-causing proteins at the molecular level. The immunotherapeutic approach with the phosphorothioate oligodeoxynucleotide AP 12009 for the treatment of malignant tumors is based on the specific inhibition of TGF-beta2. [ABSTRACT FROM AUTHOR] |
| Database: |
Supplemental Index |